Investigational Drug Information for Fevipiprant
✉ Email this page to a colleague
What is the drug development status for Fevipiprant?
Fevipiprant is an investigational drug.
There have been 8 clinical trials for Fevipiprant.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2018.
The most common disease conditions in clinical trials are Asthma, Lung Diseases, and Hypersensitivity. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are sixteen US patents protecting this investigational drug and two hundred and thirty-six international patents.
Summary for Fevipiprant
| US Patents | 16 |
| International Patents | 236 |
| US Patent Applications | 66 |
| WIPO Patent Applications | 50 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 3 (2018-12-13) |
| Vendors | 51 |
Recent Clinical Trials for Fevipiprant
| Title | Sponsor | Phase |
|---|---|---|
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. | Novartis Pharmaceuticals | Phase 2 |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia | Novartis Pharmaceuticals | Phase 2 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Fevipiprant
Top disease conditions for Fevipiprant
Top clinical trial sponsors for Fevipiprant
US Patents for Fevipiprant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fevipiprant | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Fevipiprant | ⤷ Sign Up | Therapeutic compounds and compositions, and methods of use thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Fevipiprant | ⤷ Sign Up | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| Fevipiprant | ⤷ Sign Up | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (Basel, CH) | ⤷ Sign Up |
| Fevipiprant | ⤷ Sign Up | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | ⤷ Sign Up | |
| Fevipiprant | ⤷ Sign Up | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (Lianyungang, CN) | ⤷ Sign Up |
| Fevipiprant | ⤷ Sign Up | 5 to 7 membered heterocyclic amides as JAK inhibitors | Theravance Biopharma R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fevipiprant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fevipiprant | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | Japan | JP2019520866 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
